SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-21-043094
Filing Date
2021-08-10
Accepted
2021-08-10 16:16:29
Documents
68
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 Q2 2021 10-Q fnch-10q_20210630.htm   iXBRL 10-Q 3116530
2 EX-31.1 fnch-ex311_7.htm EX-31.1 20731
3 EX-31.2 fnch-ex312_6.htm EX-31.2 21147
4 EX-32.1 fnch-ex321_8.htm EX-32.1 16923
  Complete submission text file 0001564590-21-043094.txt   8206318

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA fnch-20210630.xsd EX-101.SCH 55600
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE fnch-20210630_cal.xml EX-101.CAL 44223
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE fnch-20210630_def.xml EX-101.DEF 215724
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE fnch-20210630_lab.xml EX-101.LAB 407227
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fnch-20210630_pre.xml EX-101.PRE 327605
10 EXTRACTED XBRL INSTANCE DOCUMENT fnch-10q_20210630_htm.xml XML 1082378
Mailing Address 200 INNER BELT ROAD SOMERVILLE MA 02143
Business Address 200 INNER BELT ROAD SOMERVILLE MA 02143 617-229-6499
Finch Therapeutics Group, Inc. (Filer) CIK: 0001733257 (see all company filings)

IRS No.: 823433558 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40227 | Film No.: 211160107
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences